Evidence map›Paper›PMID 26306393›Full record

ArticleCritical care (London, England)2015

Rifampin use in acute community-acquired meningitis in intensive care units: the French retrospective cohort ACAM-ICU study.

Cédric Bretonnière, Mathieu Jozwiak, Christophe Girault, Pascal Beuret, Jean-Louis Trouillet, Nadia Anguel, Jocelyne Caillon, Gilles Potel, Daniel Villers, David Boutoille and 1 more

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in Critical care (London, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. What's new in bacterial meningitis.Intensive care medicine · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Cédric BretonnièreService de Réanimation Médicale Polyvalente, CHU Nantes, Pôle Hospitalo-universitaire 3, place A. Ricordeau, Nantes, F-44093, France. cedric.bretonniere@chu-nantes.fr.
Mathieu JozwiakService de Réanimation Médicale Polyvalente, CHU Nantes, Pôle Hospitalo-universitaire 3, place A. Ricordeau, Nantes, F-44093, France. mathieu.jozwiak@aphp.fr.
Christophe GiraultService de Réanimation Médicale Polyvalente, CHU-Hôpitaux de Rouen, Hôpital Charles Nicolle, 1 rue de Germont, Rouen, F-76000, France. christophe.girault@chu-rouen.fr.
Pascal BeuretCH Roanne, Service de Réanimation Médico-chirurgicale, 28 rue de Charlieu, Roanne, F-42300, France. pascal.beuret@ch-roanne.fr.
Jean-Louis TrouilletService de Réanimation Médicale, AP-HP, Hôpital de la Pitié-Salpêtrière, Institut de Cardiologie, 47-53 boulevard de l'Hôpital, Paris, F-75651, France. jean-louis.trouillet@psl.aphp.fr.
Nadia AnguelService de Réanimation Médicale, AP-HP, Hôpitaux universitaires Paris-Sud, Hôpital de Bicêtre, 78 rue du Général Leclerc, Le Kremlin-Bicêtre, F-94270, France. nadia.anguel@aphp.fr.
Jocelyne CaillonFaculté de Médecine, Université de Nantes, UPRES EA 3826, 1 rue Gaston Veil, Nantes, F-44035, France. jocelyne.caillon@univ-nantes.fr.
Gilles PotelFaculté de Médecine, Université de Nantes, UPRES EA 3826, 1 rue Gaston Veil, Nantes, F-44035, France. gilles.potel@chu-nantes.fr.
Daniel VillersService de Réanimation Médicale Polyvalente, CHU Nantes, Pôle Hospitalo-universitaire 3, place A. Ricordeau, Nantes, F-44093, France. daniel.villers@chu-nantes.fr.
David BoutoilleFaculté de Médecine, Université de Nantes, UPRES EA 3826, 1 rue Gaston Veil, Nantes, F-44035, France. david.boutoille@chu-nantes.fr.
Christophe GuittonService de Réanimation Médicale Polyvalente, CHU Nantes, Pôle Hospitalo-universitaire 3, place A. Ricordeau, Nantes, F-44093, France. christophe.guitton@chu-nantes.fr.
Centre Hospitalier Universitaire de Nantes · FRAssistance Publique – Hôpitaux de Paris · FRHôpital Charles-Nicolle · FRImation (United States) · USSorbonne Université · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionBacterial meningitis among critically ill adult patients remains associated with both high mortality and frequent, persistent disability. Vancomycin was added to treatment with a third-generation cephalosporin as recommended by French national guidelines. Because animal model studies had suggested interest in the use of rifampin for treatment of bacterial meningitis, and after the introduction of early corticosteroid therapy (in 2002), there was a trend toward increasing rifampin use for intensive care unit (ICU) patients. The aim of this article is to report on this practice.

methodsFive ICUs participated in the study. Baseline characteristics and treatment data were retrospectively collected from charts of patients admitted with a diagnosis of acute bacterial meningitis during a 5-year period (2004-2008). The ICU mortality was the main outcome measure; Glasgow Outcome Scale and 3-month mortality were also assessed.

resultsOne hundred fifty-seven patients were included. Streptococcus pneumoniae and Neisseria meningitidis were the most prevalent causative microorganisms. The ICU mortality rate was 15%. High doses of a cephalosporin were the most prevalent initial antimicrobial treatment. The delay between admission and administration of the first antibiotic dose was correlated with ICU mortality. Rifampin was used with a cephalosporin for 32 patients (ranging from 8% of the cohort for 2004 to 30% in 2008). Administration of rifampin within the first 24 h of hospitalization could be associated with a lower ICU survival. Statistical association between such an early rifampin treatment and ICU mortality reached significance only for patients with pneumococcal meningitis (p=0.031) in univariate analysis, but not in the logistic model.

conclusionsWe report on the role of rifampin use for patients with community-acquired meningitis, and the results of this study suggest that this practice may be associated with lower mortality in the ICU. Nevertheless, the only independent predictors of ICU mortality were organ failure and pneumococcal infection. Further studies are required to confirm these results and to explain how rifampin use would reduce mortality.

Indexed as

Anti-Bacterial AgentsCommunity-Acquired InfectionsFemaleFranceGlasgow Outcome ScaleHospital MortalityHumansIntensive Care UnitsMaleMeningitis, BacterialMeningitis, MeningococcalMeningitis, PneumococcalMiddle AgedNeisseria meningitidisRetrospective StudiesRifampinAnti-Bacterial AgentsRifampin

Identifiers

PMID26306393
PMCPMC4549935
OpenAlexW1957527125

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.